علاج تجلط الوريد الطحالي في تجلط الأوردة الحشوية الحادة العرضي المرتبط بالسرطان

References

• In patients with cancer-associated symptomatic acute splanchnic vein thrombosis, we recommend LMWH or DOACs. We suggest LMWH in patients with luminal gastrointestinal cancer, active gastrointestinal mucosal abnormalities, genitourinary cancer at high risk of bleeding, or receiving current systemic therapy with potentially relevant drug-drug interactions with DOACs.
• 3 to 6-month anticoagulation irrespective of thrombosis extension and underlying risk factors.
• Longer course or indefinite anticoagulation if: thrombosis progression or recurrence after treatment discontinuation; unprovoked splanchnic vein thrombosis; persistent thrombotic risk factor.
• Treatment of occlusive or non-occlusive acute splanchnic vein thrombosis aims to prevent intestinal infarction or ischemia, and achieve the highest possible vessel recanalization to reduce splanchnic hypertension and bleeding risk.